GE HealthCare Technologies Inc.
Shortcut
1.20Normalized diluted EPS
+0.3% vs Street
Street
1.20Normalized diluted EPS
October 25 consensus snapshot
Real
1.34Issuer adjusted diluted EPS
Model download
Explore the assumptions and calculations behind the forecast.
Shortcut’s reasoning.
Issuer guided 3Q26 on 29-Jul-26 to organic growth of 3–4% and "low double-digit" adjusted EPS growth on $1.07 (≈$1.18–1.21); the model lands at $1.20, inside that range and on the frozen $1.20 consensus.
Revenue $5,367M (+4.4% Y/Y): organic +3.9% (record $23.9B backlog, ~85% of equipment revenue secured entering 3Q, PDx +12% on contrast/radiopharma demand, PCS still −6%), Intelerad +$63M, FX ≈ −$37M (EUR/USD −1.5% Y/Y).
Adjusted EBIT $823M (15.3% margin, +50 bps Y/Y): AIS 14.8% and PDx 29.5% segment margins with price actions lagging into 2H, offset by memory-chip/oil/freight inflation and a PCS margin near break-even.
On the record.
- Reporting period
- Q3 2026 (FQ3 2026 — quarter ended 30-Sep-2026; supplied "Sep 2026" label preserved)
- Reporting basis
- consensus normalized issuer adjusted diluted EPS, USD per common share
- Consensus snapshot
- October 25, 2026
- Model / effort
- Opus 5.5 · High effort
- Workbook
- Reviewed workbook
Record history
- Forecast generated
- Oct 26, 2026 at 3:15 PM PDT
- Reviewed revision completed
- Oct 26, 2026 at 3:15 PM PDT
- First published
- Oct 26, 2026 at 4:00 PM PDT
Result basis
GE HealthCare reports adjusted diluted EPS $1.34 and GAAP diluted EPS $1.36 for September 30, 2026. Its adjusted-EPS table excludes tariff refunds of $0.02/share among other reconciling items, using 453m diluted shares. Score uses the published issuer-adjusted basis, not GAAP or an added-back refund.